5-HT3 receptor antagonists may be more effective against radiotherapy-induced vomiting (NNT 2.5) than metoclopramide.
A systematic review 1 including 5 studies with a total of 474 subjects was abstracted in DARE. Ondansetron was significantly more efficacious than metoclopramide for the complete control of acute vomiting (relative benefit 1.98, 95% CI: 1.47, 2.65; NNT 2.2) and acute nausea (relative benefit 1.71, 95% CI: 1.17, 2.51; NNT 3.6) in a placebo-controlled trial. Granisetron was significantly better than metoclopramide in preventing vomiting and mild nausea (relative benefit 4.0, 95% CI: 1.01, 15.8; NNT 2.5). There is no evidence that these drugs are of any benefit beyond 24 hours.
Comment: The quality of evidence is downgraded by potential reporting bias and limitations in review methodology.
. Tramèr MR, Reynolds DJ, Stoner NS, Moore RA, McQuay HJ. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. Eur J Cancer 1998 Nov;34(12):1836-44. [PMID:10023303]
Copyright © 2023 Duodecim Medical Publications Limited.
5-HT3 receptor antagonists for radiotherapy-induced nausea and vomiting
is a sample topic from the Evidence-Based Medicine Guidelines
To view other topics, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.
"5-HT3 Receptor Antagonists for Radiotherapy-induced Nausea and Vomiting." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455388/all/__________5_HT3_receptor_antagonists_for_radiotherapy_induced_nausea_and_vomiting______.
5-HT3 receptor antagonists for radiotherapy-induced nausea and vomiting. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455388/all/__________5_HT3_receptor_antagonists_for_radiotherapy_induced_nausea_and_vomiting______. Accessed March 30, 2023.
5-HT3 receptor antagonists for radiotherapy-induced nausea and vomiting. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/455388/all/__________5_HT3_receptor_antagonists_for_radiotherapy_induced_nausea_and_vomiting______
5-HT3 Receptor Antagonists for Radiotherapy-induced Nausea and Vomiting [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 30]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455388/all/__________5_HT3_receptor_antagonists_for_radiotherapy_induced_nausea_and_vomiting______.
TY - ELEC
T1 - 5-HT3 receptor antagonists for radiotherapy-induced nausea and vomiting
ID - 455388
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455388/all/__________5_HT3_receptor_antagonists_for_radiotherapy_induced_nausea_and_vomiting______
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine